2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106245
    HT-0712 617720-02-2
    HT-0712 is a Phosphodiesterase Type 4 (PDE4) inhibitor. HT-0712 enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia.
    HT-0712
  • HY-106334
    Noberastine 110588-56-2
    Noberastine is a potent Histamine H1 antagonist. Noberastine has specific peripheral antihistamine activity .
    Noberastine
  • HY-106345
    ILS-920 892494-07-4
    ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12.
    ILS-920
  • HY-106361
    Flerobuterol 82101-10-8
    Flerobuterol is a beta-adrenoceptor agonist with antidepressant activity. Flerobuterol enhances serotonergic neurotransmission.
    Flerobuterol
  • HY-106379
    Lurosetron 128486-54-4
    Lurosetron (GR-87442) is a 6-fluoro analogue of Alosetron (HY-70050A). Lurosetron is a serotonin 5-HT3 receptor antagonist. Lurosetron inhibits recombinant (rbt) CYP1A2, with an IC50 of 0.1 μM. Lurosetron also inhibits other CYP isoforms, including rbtCYP2C9 and rbtCYP3A4 with IC50s ranging between 3.5 μM and 16 μM..
    Lurosetron
  • HY-106397
    Delucemine 186495-49-8
    Delucemine is a selective serotonin reuptake inhibitor (SSRI) and NMDAR antagonist. Delucemine can be used as an antidepressant.
    Delucemine
  • HY-106424
    Soretolide 130403-08-6
    Soretolide is an antiepileptic agent. Soretolide is effective in maximal electroshock-induced seizure (MES) test in rodents. Soretolide inhibits metabolism of Phenytoin (HY-B0448). Soretolide exhibits a good pharmacokinetic character in rats model.
    Soretolide
  • HY-106430
    Piclozotan 182415-09-4
    Piclozotan (SUN N4057) is a 5HT1A receptor agonist. Piclozotan improves motor complications in Parkinson's disease model.
    Piclozotan
  • HY-106432
    Sabcomeline 159912-53-5
    Sabcomeline (SB-202026) is a potent and functionally selective muscarinic M1 receptor partial agonist that improve cognition. Sabcomeline can be used for Alzheimer's disease research.
    Sabcomeline
  • HY-106439
    BTG 1640 152538-59-5
    BTG 1640 (ABIO-08/01) is a potent anxiolytic isoxazoline. BTG 1640 is a selective inhibitor of GABA- and glutamate-gated chloride channels.
    BTG 1640
  • HY-106444
    Fipamezole 150586-58-6
    Fipamezole (MPV 1730; JP-1730) is a potent and orally active α2-adrenergic receptor antagonist with Ki values of 9.2 nM, 17 nM, and 55 nM for human α2A, α2B, and α2C, receptors, respectively. Fipamezole is an anti-dyskinetic agent, and can be used for the study of Parkinson's disease.
    Fipamezole
  • HY-106467
    Caroverine 23465-76-1
    Caroverine is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine can be used for the research of inner ear tinnitus.
    Caroverine
  • HY-106469
    Taltrimide 81428-04-8
    Taltrimide (MY-117), a lipophilic derivative of Taurine (HY-B0351), strongly inhibits the sodium-independent binding of Taurine to synaptic membranes of brain, the effects on the binding of GABA being less pronounced. Taltrimide exhibits definitive anticonvulsive effects in experimental epilepsy models.
    Taltrimide
  • HY-106474
    Meribendan 119322-27-9
    Meribendan is a phosphodiesterase (PDE)-III inhibitor.
    Meribendan
  • HY-106484
    Tiflucarbine 89875-86-5
    Tiflucarbine (BAY-P 4495) is a tetrahydrothieno-7-carboline derivative. Tiflucarbine is a potent antidepressant agent that binds at central serotonin (5-HT) binding sites. Tiflucarbine is a nonselective 5-HT (5-HT1 and 5-HT2) agonist.
    Tiflucarbine
  • HY-106487
    Pridefine 5370-41-2
    Pridefine (AHR-1118) is an antidepressant agent.
    Pridefine
  • HY-106495
    Vadocaine 72005-58-4
    Vadocaine (OR K-242), an orally active antitussive compound, is a local agent that can suppress or relieve pain.
    Vadocaine
  • HY-106516
    Napactadine free base 76631-45-3
    Napactadine (free base) (compound 33) has anti-depressive activity. Napactadine has oral activity.
    Napactadine free base
  • HY-106547
    Rilmazafone 99593-25-6
    Rilmazafone is a benzodiazepine (omega) ligand and an orally active sleep inducer.
    Rilmazafone
  • HY-106578
    Quinupramine 31721-17-2
    Quinupramine is an orally active antidepressant. Quinupramine can penetrate into the CNS and affect some of the processes of neurotransmission. The antidepressant activity of quinupramine is associated with the central serotonin system, but not with the β-adrenergic system[1][2].
    Quinupramine
Cat. No. Product Name / Synonyms Application Reactivity